EUVIMEDEUVIMED entdecken
Leserbrief

Improvement in mucosal discoid lupus erythematosus with anifrolumab

Katharina Shaw iD, Dustin Taylor, Stephanie Sanchez-Melendez, Julia Barker, Sarah Lonowski, Neda Shahriari, Hannah J Porter, Keith Morley, Avery LaChance, Ruth Ann Vleugels iD

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad190 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Katharina Shaw und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anifrolumab is a fully humanized monoclonal antibody targeting the type I interferon receptor and recently approved for the treatment of moderate-to-severe systemic lupus erythematosus. In addition to ameliorating systemic lupus activity, anifrolumab has emerged as a promising therapeutic option for patients with refractory cutaneous discoid lupus erythematosus (DLE), but its effect on mucosal DLE has yet to be investigated. In a prospective study of seven patients with severe mucosal DLE treated with anifrolumab, we observed substantial improvement in mucosal disease activity within 1 month of anifrolumab initiation, suggesting that the impressive benefit of anifrolumab previously reported in cutaneous DLE extends to mucosal involvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicLupus Erythematosus, DiscoidHumansAntibodies, Monoclonal, Humanized

Substanzen

anifrolumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Division of Dermatology, University of Vermont Medical Center, Burlington, VT, USA.
  • Department of Dermatology, University of Nebraska Medical Center, Omaha, NE, USA.

ORCID-Profile: Katharina Shaw, Ruth Ann Vleugels

Zitieren

APA

Shaw, K., Taylor, D., Sanchez-Melendez, S., Barker, J., Lonowski, S., Shahriari, N., Porter, H. J., Morley, K., LaChance, A., & Vleugels, R. A. (2023). Improvement in mucosal discoid lupus erythematosus with anifrolumab. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad190

Vancouver

Shaw K, Taylor D, Sanchez-Melendez S, Barker J, Lonowski S, Shahriari N, et al. Improvement in mucosal discoid lupus erythematosus with anifrolumab. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad190

BibTeX
@article{Shaw2023,
  author = {Shaw, Katharina and Taylor, Dustin and Sanchez-Melendez, Stephanie and Barker, Julia and Lonowski, Sarah and Shahriari, Neda and Porter, Hannah J and Morley, Keith and LaChance, Avery and Vleugels, Ruth Ann},
  title = {Improvement in mucosal discoid lupus erythematosus with anifrolumab},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad190}
}
Kostenlos starten →